MultiCell is a leading-edge biopharmaceutical company committed to the development and commercialization of breakthrough therapeutics based on a portfolio of new drug candidates and patented drug development technology platforms.  MultiCell leverages patented methods of modulating the human immune system to treat serious autoimmune diseases, including multiple sclerosis and type-1 diabetes, as well as influenza and other health threats.  Currently, the market for therapies addressing such conditions is estimated at $8 billion worldwide. The Company’s novel technologies include expertise in Toll-like receptors and T-cell targeting to modulate both the innate and adaptive immune systems, enabling the creation of advanced drug candidates that stimulate or suppress the immune system via disease-specific targeting of the immune system.  Wed, Dec 26 2007 5:14 PM MultiCell Technologies To Increase Focus on Therapeutic Candidates Wed, Oct 10 2007 10:23 AM MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated Thu, July 19 2007 8:00 AM MultiCell Technologies and Fusion Capital Terminate Common Stock Purchase Agreement Thu, May 03 2007 9:00 AM MultiCell Technologies Receives Two International Trademark Protections Tue, Apr 24 2007 8:00 AM MultiCell Signs License Agreement With Eisai Japan to Use Fa2N-4 Cell Line for Drug Discovery/ADMETOX Applications Wed, Apr 18 2007 9:00 AM MultiCell Technologies Signs Key Formulation and Supply Agreement With Merck KGaA & Co. Spittal/Drau Mon, Apr 9 2007 9:30 AM MultiCell Technologies Signs Key Supply Agreement With Lundbeck Pharmaceuticals Italy S.p.A. Wed, Mar 21 2007 10:38 AM MultiCell Technologies Announces a New Class of Patented Therapeutics Tue, Mar 6 2007 7:28 PM MultiCell Technologies Completes Private Financing Agreement with La Jolla Cove Investors for up to $13 Million to Support Development of Advanced Therapeutics Thu, Feb 15 2007 3:30 AM MultiCell Technologies Announces Prospective Cancer Treatment Drug Tue, Feb 6 2007 3:30 AM MultiCell Technologies Announces Progress for MCT-125's Anticipated Phase IIb Clinical Trial Thu, Jan 11 2007 6:30 AM MultiCell Technologies' Proprietary Breakthrough Anti-Cancer Therapy Shown to Prevent Recurrence of Cancer Fri, Dec 15 2006 6:30 AM MultiCell Technologies Fulfills Upfront License Fee Payment Obligation to Amarin Neuroscience for MCT-125 Wed, Dec 6 2006 5:04 PM MultiCell Technologies Discusses Recent Cancer Treatment Breakthrough and Growing Intellectual Property Portfolio with CEOcast.com Investor Information Service Wed, Nov 29 2006 6:30 AM MultiCell Technologies Obtains Patent Protection in Several European Countries for Treatment of Autoimmune Diseases Mon, Nov 27 2006 4:01 PM MultiCell Technologies Releases CEO Letter to Shareholders Wed, Nov 22 2006 6:30 AM WebAlert: MultiCell Technologies Presenting during SmallCapInsights.com's ''Emerging Growth Forum'' Starting Today at 12 Noon ET Tue, Nov 21 2006 9:25 AM Multicell Technologies Demonstrates Drug Candidate's Powerful Tumor-Destroying Capabilities for Virally Induced Cancers such as Cervical Cancer Mon, Nov 20 2006 10:06 AM MultiCell Technologies and SmallCapInsights.com Highlight CEOs Presenting at Wednesday's Anticipated ``Emerging Growth Forum'' Mon, Nov 20 2006 9:25 AM MultiCell Technologies to Seek Advanced Human Clinical Trials for Lead Therapeutics Program Thu, Nov 16 2006 4:03 PM MultiCell Technologies Announces SmallCapInsights.com to Host ''Emerging Growth Forum'' Webcast Highlighting Auriga Laboratories, MultiCell Technologies, Peace Arch Entertainment and Titan Global Holdings Tue, Nov 7 2006 4:01 PM MultiCell Technologies CEO to Present Key Research Data at New York Academy of Sciences' Animal Models Conference Wed, Nov 01 2006 4:32 PM MultiCell Technologies Posts Journal Article on Research Leading to Company's Recent Patent Application on Novel Cancer Treatment Tue, Oct 31 2006 11:23 AM MultiCell Technologies Releases Transcript of Recent Investor Conference Call Discussing Recent Growth Initiatives and Growth of IP Portfolio Thu, Oct 26 2006 11:43 AM MultiCell Technologies Recaps New Investor Conference Call Discussing Recent Drug Development Initiatives and Strengthened IP Portfolio Wed, Oct 25 2006 06:30 AM WebAlert: MultiCell Technologies Investor Conference Call Starts Today at 12 Noon ET Thu, Oct 12 2006 4:03 PM MultiCell Technologies Announces Milestone Patent Issued by European Patent Office on Treatments for Autoimmune Diseases Wed, Oct 11 2006 4:02 PM WebAlert: MultiCell Technologies to Release CEO Interview to Discuss Progress in Business and Drug Development Programs Wed, Oct 11 2006 6:00 PM MultiCell Outlines Portfolio of Next-Generation Immune Modulation Therapeutics Technology in Updated Investor Fact Sheet Fri, Oct 6 2006 4:01 PM MultiCell Announces ?ntellectual Property Portfolio of First-in-Class Technologies Crosses Threshold of 50 Issued or Pending Patents Thu, Oct 5 2006 6:22 PM MultiCell and Fusion Capital Amend and Restate Common Stock Purchase Agreement to Provide for $8 Million of Equity Funding Thu, Oct 5 2006 6:00 PM MultiCell Technologies Announces Strategic Initiatives for 2006 and 2007; Company to Focus on Advance of First-in-Class Immune-based Drug Candidates into Advanced Phase Human Clinical Trials Tue, Oct 3 2006 3:03 PM SmallCapInsights.com Investment Newsletter Commences Editorial Coverage of MultiCell Technologies Following Recently Filed Patent on Cancer Treatment [more news...]